{"id":2990,"date":"2021-11-30T11:11:16","date_gmt":"2021-11-30T11:11:16","guid":{"rendered":"https:\/\/aceoncology.org\/?p=2990"},"modified":"2021-11-30T11:11:18","modified_gmt":"2021-11-30T11:11:18","slug":"nivolumab-ipilimumab-combo-followed-by-braf-mek-inhibitors-should-be-preferred-treatment-sequence-for-patients-with-braf-mutant-melanoma","status":"publish","type":"post","link":"https:\/\/aceoncology.org\/zh-hans\/nivolumab-ipilimumab-combo-followed-by-braf-mek-inhibitors-should-be-preferred-treatment-sequence-for-patients-with-braf-mutant-melanoma\/","title":{"rendered":"\u514d\u75ab\u6cbb\u7597\u5e94\u4f5c\u4e3aBRAF V600\u7a81\u53d8\u578b\u9ed1\u8272\u7d20\u7624\u7684\u521d\u59cb\u65b9\u6848"},"content":{"rendered":"\n<p>\u7ea650%\u7684\u665a\u671f\u9ed1\u8272\u7d20\u7624\u60a3\u8005\u5b58\u5728\u6fc0\u6d3b\u7684BRAF V600\u7a81\u53d8\u3002\u9776\u5411\u6cbb\u7597\u7ec4\u5408BRAF\/MEK\u6291\u5236\u5242\uff08\u5982<a href=\"https:\/\/www.nejm.org\/doi\/10.1056\/NEJMoa1904059?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub%20%200pubmed\">\u8fbe\u62c9\u975e\u5c3c\/\u66f2\u7f8e\u66ff\u5c3c<\/a>\uff09\u548c\u514d\u75ab\u68c0\u67e5\u70b9\u6291\u5236\u5242\u7ec4\u5408\uff08\u5982<a href=\"https:\/\/ascopubs.org\/doi\/abs\/10.1200\/JCO.2021.39.15_suppl.9506\">\u7eb3\u6b66\u5229\u5c24\u5355\u6297\/\u4f0a\u5339\u6728\u5355\u6297<\/a>\uff09\u5728\u6b64\u7c7b\u60a3\u8005\u4e2d\u5747\u663e\u793a\u51fa\u4e86\u663e\u8457\u7684\u751f\u5b58\u83b7\u76ca\u3002\u7136\u800c\uff0c\u8fd9\u4e9b\u60a3\u8005\u7684\u6700\u4f73\u524d\u671f\u6cbb\u7597\u65b9\u6cd5\u5c1a\u4e0d\u660e\u786e\u3002\u76ee\u524d\u5728\u7f8e\u56fd\uff0c\u7ea6\u534a\u6570\u7684BRAF\u7a81\u53d8\u60a3\u8005\u63a5\u53d7BRAF\/MEK\u6291\u5236\u5242\u8054\u5408\u6cbb\u7597\uff0c\u7ea6\u56db\u5206\u4e4b\u4e00\u7684\u60a3\u8005\u7684\u521d\u59cb\u6cbb\u7597\u65b9\u6848\u662f\u7eb3\u6b66\u5229\u5c24\u5355\u6297\/\u4f0a\u5339\u6728\u5355\u6297\u7684\u8054\u5408\u6cbb\u7597\u3002\u8be5\u7814\u7a76\u5c06\u786e\u5b9a\u514d\u75ab\u6cbb\u7597\u548c\u9776\u5411\u6cbb\u7597\u7684\u6700\u4f73\u6cbb\u7597\u987a\u5e8f\uff0c\u5176\u7ed3\u679c\u503c\u5f97\u77a9\u76ee\u3002<\/p>\n\n\n\n<p>ASCO\u5168\u4f53\u4f1a\u8bae\u7cfb\u5217\u7684\u5f00\u573a\u4f1a\u8bae\u65e8\u5728\u4ecb\u7ecdASCO\u671f\u95f4\u5c06\u516c\u5e03\u7684\u5f71\u54cd\u4e34\u5e8a\u5b9e\u8df5\u7684\u7814\u7a76\uff0c\u8be5\u4f1a\u8bae\u4e0a\uff0c\u6765\u81ea\u7f8e\u56fd\u534e\u76db\u987f\u4e54\u6cbb\u57ceLombardi\u7efc\u5408\u80bf\u7624\u4e2d\u5fc3\u7684Michael Atkins\u535a\u58eb\u4ecb\u7ecd\u4e86\u665a\u671f\u9ed1\u8272\u7d20\u7624\u968f\u673a\u3001<a href=\"https:\/\/d32wbias3z7pxg.cloudfront.net\/meeting\/294\/abstract\/pdf\/294-14130-204473.pdf\">III \u671fDREAMseq \u7814\u7a76<\/a>\u7684\u7ed3\u679c\u3002\u8be5\u7814\u7a76\u7684\u76ee\u7684\u662f\u786e\u5b9a\u65e2\u5f80\u672a\u7ecf\u6cbb\u7597\u7684BRAF V600\u7a81\u53d8\u665a\u671f\u9ed1\u8272\u7d20\u7624\u60a3\u8005\u7684\u6700\u4f73\u6cbb\u7597\u987a\u5e8f\u3002\u7814\u7a76\u5bf9\u6bd4\u4e86\u75be\u75c5\u8fdb\u5c55\u65f6\u7eb3\u6b66\u5229\u5c24\u5355\u6297\/\u4f0a\u5339\u6728\u5355\u6297\uff084\u4e2a\u5468\u671f\u7684\u514d\u75ab\u6cbb\u7597\u8054\u5408\u6cbb\u7597\uff0c\u7136\u540e\u7eb3\u6b66\u5229\u5c24\u5355\u6297\u7ef4\u6301\u6cbb\u7597\uff09\u5e8f\u8d2f\u8fbe\u62c9\u975e\u5c3c\/\u66f2\u7f8e\u66ff\u5c3c\u9776\u5411\u6cbb\u7597\uff0c\u4e0e\u8f6c\u6362\u987a\u5e8f\uff08\u5148\u9776\u5411\u6cbb\u7597\uff0c\u7136\u540e\u514d\u75ab\u6cbb\u7597\uff09\u7684\u7597\u6548\u3002\u6839\u636eECOG\u4f53\u80fd\u72b6\u6001\uff080\u5206\/1\u5206\uff09\u548c\u4e73\u9178\u8131\u6c22\u9176\uff08LDH\uff09\u72b6\u6001\uff08\u6b63\u5e38\/\u9ad8\uff09\u5bf9265\u540d\u8fdb\u884c\u5206\u5c42\uff0c\u5e76\u5728\u201c\u7b2c1\u9636\u6bb5\u201d\u4e2d\u968f\u673a\u63a5\u53d7\u7eb3\u6b66\u5229\u5c24\u5355\u6297\/\u4f0a\u5339\u6728\u5355\u6297\uff08A\u7ec4\uff0cn = 133\uff09\u6216\u8fbe\u62c9\u975e\u5c3c\/\u66f2\u7f8e\u66ff\u5c3c\uff08B\u7ec4\uff0cn = 132\uff09\u6cbb\u7597\u3002<\/p>\n\n\n\n<p>\u5982\u679c\u60a3\u8005\u51fa\u73b0\u75be\u75c5\u8fdb\u5c55\uff0c\u5219\u4ea4\u53c9\u81f3\u201c\u7b2c2\u9636\u6bb5\u201d\u63a5\u53d7\u8f6c\u6362\u6cbb\u7597\u3002\u5171\u670973\u4f8b\u60a3\u8005\u7b26\u5408\u4ea4\u53c9\u6761\u4ef6\uff0c46\u4f8b\u60a3\u8005\u63a5\u53d7\u514d\u75ab\u6cbb\u7597\uff08D\u7ec4\uff09\uff0c27\u4f8b\u60a3\u8005\u63a5\u53d7\u8fbe\u62c9\u975e\u5c3c\/\u66f2\u7f8e\u66ff\u5c3c\uff08C\u7ec4\uff09\u3002\u4e2d\u4f4d\u968f\u8bbf\u65f6\u95f4\u4e3a27.7\u4e2a\u6708\u3002\u7ed3\u679c\u663e\u793a\uff0c\u514d\u75ab\u6cbb\u7597\u4f5c\u4e3a\u521d\u59cb\u6cbb\u7597\u7684\u60a3\u80052\u5e74\u751f\u5b58\u7387\u4e3a72%\uff0c\u800c\u9776\u5411\u6cbb\u7597\u4f5c\u4e3a\u521d\u59cb\u6cbb\u7597\u7684\u60a3\u8005\u5bf9\u5e94\u6570\u636e\u4e3a52%\uff08log-rank P = 0.0095\uff09\u3002\u6cbb\u759710\u4e2a\u6708\u540e\uff0c\u514d\u75ab\u6cbb\u7597\u4f5c\u4e3a\u521d\u59cb\u6cbb\u7597\u7684\u603b\u751f\u5b58\u671f\uff08OS\uff09\u4f18\u52bf\u53d8\u5f97\u660e\u663e\u3002\u6b64\u5916\uff0c\u4e00\u7ebf\u7eb3\u6b66\u5229\u5c24\u5355\u6297\/\u4f0a\u5339\u6728\u5355\u6297\u5e26\u6765\u66f4\u957f\u7684\u7f13\u89e3\u6301\u7eed\u65f6\u95f4\uff08\u672a\u8fbe\u5230vs. 12.7\u4e2a\u6708\uff1bP &lt; 0.001\uff09\u3002\u503c\u5f97\u6ce8\u610f\u7684\u662f\uff0c\u514d\u75ab\u6cbb\u7597\u4f5c\u4e3a\u524d\u671f\u6cbb\u7597\u76842\u5e74OS\u83b7\u76ca\u89c1\u4e8e\u6240\u6709\u4e9a\u7ec4\uff0c\u5305\u62ecPS0\u3001LDH\u6b63\u5e38\u548c\u5206\u671f\u2264M1c\u7684\u4e9a\u7ec4\u3002\u4e24\u7ec4\u4e4b\u95f43\u7ea7\u53ca\u4ee5\u4e0a\u6cbb\u7597\u76f8\u5173\u4e0d\u826f\u4e8b\u4ef6\u53d1\u751f\u7387\u76f8\u4f3c\uff0c\u7b2c1\u9636\u6bb5\u4e3a60% vs. 52%\uff0c\u7b2c2\u9636\u6bb5\u4e3a54%vs. 50%\u3002\u7b2c1\u9636\u6bb5\u4e2d\u514d\u75ab\u6cbb\u7597\u7ec4\u67092\u4f8b\u6cbb\u7597\u76f8\u5173\u6b7b\u4ea1\uff0c\u6b7b\u4e8e\u5fc3\u808c\u708e\u548c\u80c3\u80a0\u9053\u6bd2\u6027\uff0c\u7b2c2\u9636\u6bb5\u4e2d\u9776\u5411\u6cbb\u7597\u7ec4\u67091\u4f8b\u6b7b\u4ea1\uff0c\u6b7b\u4e8e\u5352\u4e2d\u3002<\/p>\n\n\n\n<p>Atkins\u5f97\u51fa\u7ed3\u8bba\uff0c\u8be5\u7814\u7a76\u7ed3\u679c\u5c06\u6539\u53d8\u4e34\u5e8a\u5b9e\u8df5\uff0c\u201c\u7eb3\u6b66\u5229\u5c24\u5355\u6297\/\u4f0a\u5339\u6728\u5355\u6297\u521d\u59cb\u6cbb\u7597\u540eBRAF\/MEK\u6291\u5236\u5242\u6cbb\u7597\uff08\u5982\u6709\u5fc5\u8981\uff09\u662fBRAF\u7a81\u53d8\u578b\u9ed1\u8272\u7d20\u7624\u60a3\u8005\u7684\u9996\u9009\u6cbb\u7597\u987a\u5e8f\u201d\u3002\u6765\u81eaDana-Farber\u80bf\u7624\u7814\u7a76\u6240\u3001\u54c8\u4f5b\u533b\u5b66\u9662\u53ca\u9ebb\u7701\u603b\u533b\u9662\u7684\u8ba8\u8bba\u5609\u5bbeKeith Flaherty\u535a\u58eb\u5f3a\u8c03\uff0c\u5bf9\u4e8e\u75be\u75c5\u8d1f\u62c5\u9ad8\u4e14PD-1\/CTLA-4\u8054\u5408\u514d\u75ab\u6cbb\u7597\u7684\u6bd2\u6027\u7279\u5f81\u4e0d\u660e\u663e\u7684\u60a3\u8005\uff0c\u7eb3\u6b66\u5229\u5c24\u5355\u6297\/\u4f0a\u5339\u6728\u5355\u6297\u53ef\u80fd\u662f\u6700\u4f73\u521d\u59cb\u6cbb\u7597\u9009\u62e9\u3002\u4ed6\u8fd8\u6307\u51fa\uff0cPD-1\u5355\u836f\u6cbb\u7597\u662f\u4f4e\u98ce\u9669\u60a3\u8005\u5e38\u7528\u7684\u7b56\u7565\uff0c\u56e0\u4e3a\u5176\u6cbb\u7597\u6307\u6570\u9ad8\uff0c\u7eb3\u6b66\u5229\u5c24\u5355\u6297\/\u4f0a\u5339\u6728\u5355\u6297\u8054\u5408\u6cbb\u7597\u4ece\u672a\u8868\u73b0\u51fa\u4f18\u4e8ePD-1\u5355\u836f\u6cbb\u7597\u7684\u7ed3\u5c40\u3002\u4ed6\u5f3a\u8c03\uff0c\u8fd9\u4ecd\u7136\u662f\u4e00\u4e2a\u91cd\u8981\u7684\u4e14\u5c1a\u672a\u56de\u7b54\u7684\u95ee\u9898\u3002<\/p>\n\n\n\n<p><strong>\u53c2\u8003\u6587\u732e<br><\/strong>Atkins, MB et al. <em>J Clin Oncol. <\/em>2021;39 (suppl 36): Abstract 356154.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>\u7ea650%\u7684\u665a\u671f\u9ed1\u8272\u7d20\u7624\u60a3\u8005\u5b58\u5728\u6fc0\u6d3b\u7684BRAF V600\u7a81\u53d8\u3002\u9776\u5411\u6cbb\u7597\u7ec4\u5408BRAF\/MEK\u6291\u5236\u5242\uff08\u5982\u8fbe\u62c9\u975e\u5c3c\/\u66f2 [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":2988,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[78],"tags":[],"class_list":["post-2990","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-78"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.8 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>\u514d\u75ab\u6cbb\u7597\u5e94\u4f5c\u4e3aBRAF V600\u7a81\u53d8\u578b\u9ed1\u8272\u7d20\u7624\u7684\u521d\u59cb\u65b9\u6848 - ACE Oncology<\/title>\n<meta name=\"description\" content=\"\u7eb3\u6b66\u5229\u5c24\u5355\u6297\/\u4f0a\u5339\u6728\u5355\u6297\u7ec4\u5408\u5e8f\u8d2fBRAF\/MEK\u6291\u5236\u5242\u7ec4\u5408\u53ef\u6539\u5584BRAF V600\u7a81\u53d8\u578b\u665a\u671f\u9ed1\u8272\u7d20\u7624\u60a3\u8005\u7684\u603b\u4f53\u751f\u5b58\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/aceoncology.org\/zh-hans\/nivolumab-ipilimumab-combo-followed-by-braf-mek-inhibitors-should-be-preferred-treatment-sequence-for-patients-with-braf-mutant-melanoma\/\" \/>\n<meta property=\"og:locale\" content=\"zh_CN\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"\u514d\u75ab\u6cbb\u7597\u5e94\u4f5c\u4e3aBRAF V600\u7a81\u53d8\u578b\u9ed1\u8272\u7d20\u7624\u7684\u521d\u59cb\u65b9\u6848 - ACE Oncology\" \/>\n<meta property=\"og:description\" content=\"\u7eb3\u6b66\u5229\u5c24\u5355\u6297\/\u4f0a\u5339\u6728\u5355\u6297\u7ec4\u5408\u5e8f\u8d2fBRAF\/MEK\u6291\u5236\u5242\u7ec4\u5408\u53ef\u6539\u5584BRAF V600\u7a81\u53d8\u578b\u665a\u671f\u9ed1\u8272\u7d20\u7624\u60a3\u8005\u7684\u603b\u4f53\u751f\u5b58\" \/>\n<meta property=\"og:url\" content=\"https:\/\/aceoncology.org\/zh-hans\/nivolumab-ipilimumab-combo-followed-by-braf-mek-inhibitors-should-be-preferred-treatment-sequence-for-patients-with-braf-mutant-melanoma\/\" \/>\n<meta property=\"og:site_name\" content=\"ACE Oncology\" \/>\n<meta property=\"article:published_time\" content=\"2021-11-30T11:11:16+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-11-30T11:11:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/aceoncology.org\/wp-content\/uploads\/2021\/11\/Picture-Blog-Post-68.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"500\" \/>\n\t<meta property=\"og:image:height\" content=\"281\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"ACE Demo\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@ace_oncology\" \/>\n<meta name=\"twitter:site\" content=\"@ace_oncology\" \/>\n<meta name=\"twitter:label1\" content=\"\u4f5c\u8005\" \/>\n\t<meta name=\"twitter:data1\" content=\"ACE Demo\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u9884\u8ba1\u9605\u8bfb\u65f6\u95f4\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 \u5206\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/nivolumab-ipilimumab-combo-followed-by-braf-mek-inhibitors-should-be-preferred-treatment-sequence-for-patients-with-braf-mutant-melanoma\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/nivolumab-ipilimumab-combo-followed-by-braf-mek-inhibitors-should-be-preferred-treatment-sequence-for-patients-with-braf-mutant-melanoma\/\"},\"author\":{\"name\":\"ACE Demo\",\"@id\":\"https:\/\/aceoncology.org\/#\/schema\/person\/b551dd0a4b75a5b349e0a71560a8b3c0\"},\"headline\":\"\u514d\u75ab\u6cbb\u7597\u5e94\u4f5c\u4e3aBRAF V600\u7a81\u53d8\u578b\u9ed1\u8272\u7d20\u7624\u7684\u521d\u59cb\u65b9\u6848\",\"datePublished\":\"2021-11-30T11:11:16+00:00\",\"dateModified\":\"2021-11-30T11:11:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/nivolumab-ipilimumab-combo-followed-by-braf-mek-inhibitors-should-be-preferred-treatment-sequence-for-patients-with-braf-mutant-melanoma\/\"},\"wordCount\":59,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/aceoncology.org\/#organization\"},\"image\":{\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/nivolumab-ipilimumab-combo-followed-by-braf-mek-inhibitors-should-be-preferred-treatment-sequence-for-patients-with-braf-mutant-melanoma\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/aceoncology.org\/wp-content\/uploads\/2021\/11\/Picture-Blog-Post-68.jpg\",\"articleSection\":[\"\u4f1a\u8bae\u901f\u9012\"],\"inLanguage\":\"zh-Hans\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/aceoncology.org\/zh-hans\/nivolumab-ipilimumab-combo-followed-by-braf-mek-inhibitors-should-be-preferred-treatment-sequence-for-patients-with-braf-mutant-melanoma\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/nivolumab-ipilimumab-combo-followed-by-braf-mek-inhibitors-should-be-preferred-treatment-sequence-for-patients-with-braf-mutant-melanoma\/\",\"url\":\"https:\/\/aceoncology.org\/zh-hans\/nivolumab-ipilimumab-combo-followed-by-braf-mek-inhibitors-should-be-preferred-treatment-sequence-for-patients-with-braf-mutant-melanoma\/\",\"name\":\"\u514d\u75ab\u6cbb\u7597\u5e94\u4f5c\u4e3aBRAF V600\u7a81\u53d8\u578b\u9ed1\u8272\u7d20\u7624\u7684\u521d\u59cb\u65b9\u6848 - ACE Oncology\",\"isPartOf\":{\"@id\":\"https:\/\/aceoncology.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/nivolumab-ipilimumab-combo-followed-by-braf-mek-inhibitors-should-be-preferred-treatment-sequence-for-patients-with-braf-mutant-melanoma\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/nivolumab-ipilimumab-combo-followed-by-braf-mek-inhibitors-should-be-preferred-treatment-sequence-for-patients-with-braf-mutant-melanoma\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/aceoncology.org\/wp-content\/uploads\/2021\/11\/Picture-Blog-Post-68.jpg\",\"datePublished\":\"2021-11-30T11:11:16+00:00\",\"dateModified\":\"2021-11-30T11:11:18+00:00\",\"description\":\"\u7eb3\u6b66\u5229\u5c24\u5355\u6297\/\u4f0a\u5339\u6728\u5355\u6297\u7ec4\u5408\u5e8f\u8d2fBRAF\/MEK\u6291\u5236\u5242\u7ec4\u5408\u53ef\u6539\u5584BRAF V600\u7a81\u53d8\u578b\u665a\u671f\u9ed1\u8272\u7d20\u7624\u60a3\u8005\u7684\u603b\u4f53\u751f\u5b58\",\"breadcrumb\":{\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/nivolumab-ipilimumab-combo-followed-by-braf-mek-inhibitors-should-be-preferred-treatment-sequence-for-patients-with-braf-mutant-melanoma\/#breadcrumb\"},\"inLanguage\":\"zh-Hans\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/aceoncology.org\/zh-hans\/nivolumab-ipilimumab-combo-followed-by-braf-mek-inhibitors-should-be-preferred-treatment-sequence-for-patients-with-braf-mutant-melanoma\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-Hans\",\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/nivolumab-ipilimumab-combo-followed-by-braf-mek-inhibitors-should-be-preferred-treatment-sequence-for-patients-with-braf-mutant-melanoma\/#primaryimage\",\"url\":\"https:\/\/aceoncology.org\/wp-content\/uploads\/2021\/11\/Picture-Blog-Post-68.jpg\",\"contentUrl\":\"https:\/\/aceoncology.org\/wp-content\/uploads\/2021\/11\/Picture-Blog-Post-68.jpg\",\"width\":500,\"height\":281},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/nivolumab-ipilimumab-combo-followed-by-braf-mek-inhibitors-should-be-preferred-treatment-sequence-for-patients-with-braf-mutant-melanoma\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"ACE Oncology\",\"item\":\"https:\/\/aceoncology.org\/zh-hans\/chinese-home\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"\u514d\u75ab\u6cbb\u7597\u5e94\u4f5c\u4e3aBRAF V600\u7a81\u53d8\u578b\u9ed1\u8272\u7d20\u7624\u7684\u521d\u59cb\u65b9\u6848\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/aceoncology.org\/#website\",\"url\":\"https:\/\/aceoncology.org\/\",\"name\":\"ACE Oncology\",\"description\":\"ACE Oncology is a global independent medical education resource that provides evidence-based, high-quality educational solutions for clinicians that treat patients with cancer.\",\"publisher\":{\"@id\":\"https:\/\/aceoncology.org\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/aceoncology.org\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"zh-Hans\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/aceoncology.org\/#organization\",\"name\":\"ACE Oncology\",\"url\":\"https:\/\/aceoncology.org\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-Hans\",\"@id\":\"https:\/\/aceoncology.org\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/aceoncology.org\/wp-content\/uploads\/2021\/05\/Logo.png\",\"contentUrl\":\"https:\/\/aceoncology.org\/wp-content\/uploads\/2021\/05\/Logo.png\",\"width\":156,\"height\":83,\"caption\":\"ACE Oncology\"},\"image\":{\"@id\":\"https:\/\/aceoncology.org\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/x.com\/ace_oncology\",\"https:\/\/www.linkedin.com\/company\/aceoncology\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/aceoncology.org\/#\/schema\/person\/b551dd0a4b75a5b349e0a71560a8b3c0\",\"name\":\"ACE Demo\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-Hans\",\"@id\":\"https:\/\/aceoncology.org\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/5364d75bb683367c9b56b8d9914df888527c9d170b78bbc5ef94bb01125a2253?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/5364d75bb683367c9b56b8d9914df888527c9d170b78bbc5ef94bb01125a2253?s=96&d=mm&r=g\",\"caption\":\"ACE Demo\"},\"url\":\"https:\/\/aceoncology.org\/zh-hans\/author\/demo\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"\u514d\u75ab\u6cbb\u7597\u5e94\u4f5c\u4e3aBRAF V600\u7a81\u53d8\u578b\u9ed1\u8272\u7d20\u7624\u7684\u521d\u59cb\u65b9\u6848 - ACE Oncology","description":"\u7eb3\u6b66\u5229\u5c24\u5355\u6297\/\u4f0a\u5339\u6728\u5355\u6297\u7ec4\u5408\u5e8f\u8d2fBRAF\/MEK\u6291\u5236\u5242\u7ec4\u5408\u53ef\u6539\u5584BRAF V600\u7a81\u53d8\u578b\u665a\u671f\u9ed1\u8272\u7d20\u7624\u60a3\u8005\u7684\u603b\u4f53\u751f\u5b58","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/aceoncology.org\/zh-hans\/nivolumab-ipilimumab-combo-followed-by-braf-mek-inhibitors-should-be-preferred-treatment-sequence-for-patients-with-braf-mutant-melanoma\/","og_locale":"zh_CN","og_type":"article","og_title":"\u514d\u75ab\u6cbb\u7597\u5e94\u4f5c\u4e3aBRAF V600\u7a81\u53d8\u578b\u9ed1\u8272\u7d20\u7624\u7684\u521d\u59cb\u65b9\u6848 - ACE Oncology","og_description":"\u7eb3\u6b66\u5229\u5c24\u5355\u6297\/\u4f0a\u5339\u6728\u5355\u6297\u7ec4\u5408\u5e8f\u8d2fBRAF\/MEK\u6291\u5236\u5242\u7ec4\u5408\u53ef\u6539\u5584BRAF V600\u7a81\u53d8\u578b\u665a\u671f\u9ed1\u8272\u7d20\u7624\u60a3\u8005\u7684\u603b\u4f53\u751f\u5b58","og_url":"https:\/\/aceoncology.org\/zh-hans\/nivolumab-ipilimumab-combo-followed-by-braf-mek-inhibitors-should-be-preferred-treatment-sequence-for-patients-with-braf-mutant-melanoma\/","og_site_name":"ACE Oncology","article_published_time":"2021-11-30T11:11:16+00:00","article_modified_time":"2021-11-30T11:11:18+00:00","og_image":[{"width":500,"height":281,"url":"https:\/\/aceoncology.org\/wp-content\/uploads\/2021\/11\/Picture-Blog-Post-68.jpg","type":"image\/jpeg"}],"author":"ACE Demo","twitter_card":"summary_large_image","twitter_creator":"@ace_oncology","twitter_site":"@ace_oncology","twitter_misc":{"\u4f5c\u8005":"ACE Demo","\u9884\u8ba1\u9605\u8bfb\u65f6\u95f4":"1 \u5206"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/aceoncology.org\/zh-hans\/nivolumab-ipilimumab-combo-followed-by-braf-mek-inhibitors-should-be-preferred-treatment-sequence-for-patients-with-braf-mutant-melanoma\/#article","isPartOf":{"@id":"https:\/\/aceoncology.org\/zh-hans\/nivolumab-ipilimumab-combo-followed-by-braf-mek-inhibitors-should-be-preferred-treatment-sequence-for-patients-with-braf-mutant-melanoma\/"},"author":{"name":"ACE Demo","@id":"https:\/\/aceoncology.org\/#\/schema\/person\/b551dd0a4b75a5b349e0a71560a8b3c0"},"headline":"\u514d\u75ab\u6cbb\u7597\u5e94\u4f5c\u4e3aBRAF V600\u7a81\u53d8\u578b\u9ed1\u8272\u7d20\u7624\u7684\u521d\u59cb\u65b9\u6848","datePublished":"2021-11-30T11:11:16+00:00","dateModified":"2021-11-30T11:11:18+00:00","mainEntityOfPage":{"@id":"https:\/\/aceoncology.org\/zh-hans\/nivolumab-ipilimumab-combo-followed-by-braf-mek-inhibitors-should-be-preferred-treatment-sequence-for-patients-with-braf-mutant-melanoma\/"},"wordCount":59,"commentCount":0,"publisher":{"@id":"https:\/\/aceoncology.org\/#organization"},"image":{"@id":"https:\/\/aceoncology.org\/zh-hans\/nivolumab-ipilimumab-combo-followed-by-braf-mek-inhibitors-should-be-preferred-treatment-sequence-for-patients-with-braf-mutant-melanoma\/#primaryimage"},"thumbnailUrl":"https:\/\/aceoncology.org\/wp-content\/uploads\/2021\/11\/Picture-Blog-Post-68.jpg","articleSection":["\u4f1a\u8bae\u901f\u9012"],"inLanguage":"zh-Hans","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/aceoncology.org\/zh-hans\/nivolumab-ipilimumab-combo-followed-by-braf-mek-inhibitors-should-be-preferred-treatment-sequence-for-patients-with-braf-mutant-melanoma\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/aceoncology.org\/zh-hans\/nivolumab-ipilimumab-combo-followed-by-braf-mek-inhibitors-should-be-preferred-treatment-sequence-for-patients-with-braf-mutant-melanoma\/","url":"https:\/\/aceoncology.org\/zh-hans\/nivolumab-ipilimumab-combo-followed-by-braf-mek-inhibitors-should-be-preferred-treatment-sequence-for-patients-with-braf-mutant-melanoma\/","name":"\u514d\u75ab\u6cbb\u7597\u5e94\u4f5c\u4e3aBRAF V600\u7a81\u53d8\u578b\u9ed1\u8272\u7d20\u7624\u7684\u521d\u59cb\u65b9\u6848 - ACE Oncology","isPartOf":{"@id":"https:\/\/aceoncology.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/aceoncology.org\/zh-hans\/nivolumab-ipilimumab-combo-followed-by-braf-mek-inhibitors-should-be-preferred-treatment-sequence-for-patients-with-braf-mutant-melanoma\/#primaryimage"},"image":{"@id":"https:\/\/aceoncology.org\/zh-hans\/nivolumab-ipilimumab-combo-followed-by-braf-mek-inhibitors-should-be-preferred-treatment-sequence-for-patients-with-braf-mutant-melanoma\/#primaryimage"},"thumbnailUrl":"https:\/\/aceoncology.org\/wp-content\/uploads\/2021\/11\/Picture-Blog-Post-68.jpg","datePublished":"2021-11-30T11:11:16+00:00","dateModified":"2021-11-30T11:11:18+00:00","description":"\u7eb3\u6b66\u5229\u5c24\u5355\u6297\/\u4f0a\u5339\u6728\u5355\u6297\u7ec4\u5408\u5e8f\u8d2fBRAF\/MEK\u6291\u5236\u5242\u7ec4\u5408\u53ef\u6539\u5584BRAF V600\u7a81\u53d8\u578b\u665a\u671f\u9ed1\u8272\u7d20\u7624\u60a3\u8005\u7684\u603b\u4f53\u751f\u5b58","breadcrumb":{"@id":"https:\/\/aceoncology.org\/zh-hans\/nivolumab-ipilimumab-combo-followed-by-braf-mek-inhibitors-should-be-preferred-treatment-sequence-for-patients-with-braf-mutant-melanoma\/#breadcrumb"},"inLanguage":"zh-Hans","potentialAction":[{"@type":"ReadAction","target":["https:\/\/aceoncology.org\/zh-hans\/nivolumab-ipilimumab-combo-followed-by-braf-mek-inhibitors-should-be-preferred-treatment-sequence-for-patients-with-braf-mutant-melanoma\/"]}]},{"@type":"ImageObject","inLanguage":"zh-Hans","@id":"https:\/\/aceoncology.org\/zh-hans\/nivolumab-ipilimumab-combo-followed-by-braf-mek-inhibitors-should-be-preferred-treatment-sequence-for-patients-with-braf-mutant-melanoma\/#primaryimage","url":"https:\/\/aceoncology.org\/wp-content\/uploads\/2021\/11\/Picture-Blog-Post-68.jpg","contentUrl":"https:\/\/aceoncology.org\/wp-content\/uploads\/2021\/11\/Picture-Blog-Post-68.jpg","width":500,"height":281},{"@type":"BreadcrumbList","@id":"https:\/\/aceoncology.org\/zh-hans\/nivolumab-ipilimumab-combo-followed-by-braf-mek-inhibitors-should-be-preferred-treatment-sequence-for-patients-with-braf-mutant-melanoma\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"ACE Oncology","item":"https:\/\/aceoncology.org\/zh-hans\/chinese-home\/"},{"@type":"ListItem","position":2,"name":"\u514d\u75ab\u6cbb\u7597\u5e94\u4f5c\u4e3aBRAF V600\u7a81\u53d8\u578b\u9ed1\u8272\u7d20\u7624\u7684\u521d\u59cb\u65b9\u6848"}]},{"@type":"WebSite","@id":"https:\/\/aceoncology.org\/#website","url":"https:\/\/aceoncology.org\/","name":"ACE Oncology","description":"ACE Oncology is a global independent medical education resource that provides evidence-based, high-quality educational solutions for clinicians that treat patients with cancer.","publisher":{"@id":"https:\/\/aceoncology.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/aceoncology.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"zh-Hans"},{"@type":"Organization","@id":"https:\/\/aceoncology.org\/#organization","name":"ACE Oncology","url":"https:\/\/aceoncology.org\/","logo":{"@type":"ImageObject","inLanguage":"zh-Hans","@id":"https:\/\/aceoncology.org\/#\/schema\/logo\/image\/","url":"https:\/\/aceoncology.org\/wp-content\/uploads\/2021\/05\/Logo.png","contentUrl":"https:\/\/aceoncology.org\/wp-content\/uploads\/2021\/05\/Logo.png","width":156,"height":83,"caption":"ACE Oncology"},"image":{"@id":"https:\/\/aceoncology.org\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/ace_oncology","https:\/\/www.linkedin.com\/company\/aceoncology"]},{"@type":"Person","@id":"https:\/\/aceoncology.org\/#\/schema\/person\/b551dd0a4b75a5b349e0a71560a8b3c0","name":"ACE Demo","image":{"@type":"ImageObject","inLanguage":"zh-Hans","@id":"https:\/\/aceoncology.org\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/5364d75bb683367c9b56b8d9914df888527c9d170b78bbc5ef94bb01125a2253?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/5364d75bb683367c9b56b8d9914df888527c9d170b78bbc5ef94bb01125a2253?s=96&d=mm&r=g","caption":"ACE Demo"},"url":"https:\/\/aceoncology.org\/zh-hans\/author\/demo\/"}]}},"_links":{"self":[{"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/posts\/2990","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/comments?post=2990"}],"version-history":[{"count":1,"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/posts\/2990\/revisions"}],"predecessor-version":[{"id":2991,"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/posts\/2990\/revisions\/2991"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/media\/2988"}],"wp:attachment":[{"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/media?parent=2990"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/categories?post=2990"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/tags?post=2990"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}